NASDAQ:CRDF

Cardiff Oncology Competitors

$8.28
-0.50 (-5.69 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.27
Now: $8.28
$8.94
50-Day Range
$8.56
MA: $10.00
$11.49
52-Week Range
$0.82
Now: $8.28
$25.50
Volume530,917 shs
Average Volume1.72 million shs
Market Capitalization$310.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8

Competitors

Cardiff Oncology (NASDAQ:CRDF) Vs. FMTX, MESO, CRTX, ATRA, OCGN, and SRRK

Should you be buying CRDF stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cardiff Oncology, including Forma Therapeutics (FMTX), Mesoblast (MESO), Cortexyme (CRTX), Atara Biotherapeutics (ATRA), Ocugen (OCGN), and Scholar Rock (SRRK).

Forma Therapeutics (NASDAQ:FMTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

67.3% of Forma Therapeutics shares are held by institutional investors. Comparatively, 53.0% of Cardiff Oncology shares are held by institutional investors. 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Forma Therapeutics and Cardiff Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forma TherapeuticsN/A-29.54%-20.61%
Cardiff Oncology-4,990.52%-95.03%-71.77%

Valuation & Earnings

This table compares Forma Therapeutics and Cardiff Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forma Therapeutics$100.56 million12.08$-34,790,000.00N/AN/A
Cardiff Oncology$250,000.001,243.72$-16,410,000.00($2.80)-2.96

Cardiff Oncology has lower revenue, but higher earnings than Forma Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations for Forma Therapeutics and Cardiff Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forma Therapeutics00603.00
Cardiff Oncology00403.00

Forma Therapeutics currently has a consensus target price of $61.6667, indicating a potential upside of 140.42%. Cardiff Oncology has a consensus target price of $23.75, indicating a potential upside of 186.84%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Forma Therapeutics.

Summary

Forma Therapeutics beats Cardiff Oncology on 6 of the 10 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 53.0% of Cardiff Oncology shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Mesoblast and Cardiff Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Cardiff Oncology-4,990.52%-95.03%-71.77%

Valuation & Earnings

This table compares Mesoblast and Cardiff Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million36.07$-77,940,000.00($0.74)-12.08
Cardiff Oncology$250,000.001,243.72$-16,410,000.00($2.80)-2.96

Cardiff Oncology has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Mesoblast has a beta of 3.71, suggesting that its share price is 271% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Mesoblast and Cardiff Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast12302.33
Cardiff Oncology00403.00

Mesoblast currently has a consensus target price of $14.55, indicating a potential upside of 62.75%. Cardiff Oncology has a consensus target price of $23.75, indicating a potential upside of 186.84%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Mesoblast.

Cortexyme (NASDAQ:CRTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

55.5% of Cortexyme shares are held by institutional investors. Comparatively, 53.0% of Cardiff Oncology shares are held by institutional investors. 19.8% of Cortexyme shares are held by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cortexyme and Cardiff Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CortexymeN/A-37.78%-35.24%
Cardiff Oncology-4,990.52%-95.03%-71.77%

Valuation & Earnings

This table compares Cortexyme and Cardiff Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A$-36,980,000.00($1.94)-19.95
Cardiff Oncology$250,000.001,243.72$-16,410,000.00($2.80)-2.96

Cardiff Oncology has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cortexyme has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Cortexyme and Cardiff Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cortexyme21402.29
Cardiff Oncology00403.00

Cortexyme currently has a consensus target price of $50.00, indicating a potential upside of 29.20%. Cardiff Oncology has a consensus target price of $23.75, indicating a potential upside of 186.84%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Cortexyme.

Atara Biotherapeutics (NASDAQ:ATRA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Atara Biotherapeutics and Cardiff Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Cardiff Oncology00403.00

Atara Biotherapeutics currently has a consensus target price of $35.8750, indicating a potential upside of 170.14%. Cardiff Oncology has a consensus target price of $23.75, indicating a potential upside of 186.84%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Atara Biotherapeutics.

Profitability

This table compares Atara Biotherapeutics and Cardiff Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Cardiff Oncology-4,990.52%-95.03%-71.77%

Institutional & Insider Ownership

53.0% of Cardiff Oncology shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Atara Biotherapeutics and Cardiff Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-2.34
Cardiff Oncology$250,000.001,243.72$-16,410,000.00($2.80)-2.96

Cardiff Oncology has higher revenue and earnings than Atara Biotherapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Atara Biotherapeutics has a beta of 2.65, suggesting that its share price is 165% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Summary

Cardiff Oncology beats Atara Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Cardiff Oncology (NASDAQ:CRDF) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Cardiff Oncology and Ocugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiff Oncology00403.00
Ocugen01302.75

Cardiff Oncology currently has a consensus target price of $23.75, indicating a potential upside of 186.84%. Ocugen has a consensus target price of $4.80, indicating a potential downside of 16.96%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Ocugen.

Profitability

This table compares Cardiff Oncology and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiff Oncology-4,990.52%-95.03%-71.77%
OcugenN/A-47.72%-30.78%

Institutional and Insider Ownership

53.0% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Cardiff Oncology and Ocugen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$250,000.001,243.72$-16,410,000.00($2.80)-2.96
OcugenN/AN/A$-20,240,000.00($1.48)-3.91

Cardiff Oncology has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cardiff Oncology has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Summary

Cardiff Oncology beats Ocugen on 7 of the 13 factors compared between the two stocks.

Cardiff Oncology (NASDAQ:CRDF) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Cardiff Oncology and Scholar Rock, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiff Oncology00403.00
Scholar Rock00503.00

Cardiff Oncology currently has a consensus target price of $23.75, indicating a potential upside of 186.84%. Scholar Rock has a consensus target price of $61.60, indicating a potential upside of 100.19%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Scholar Rock.

Profitability

This table compares Cardiff Oncology and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiff Oncology-4,990.52%-95.03%-71.77%
Scholar Rock-365.84%-80.16%-41.33%

Institutional and Insider Ownership

53.0% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 61.9% of Scholar Rock shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by company insiders. Comparatively, 24.6% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Cardiff Oncology and Scholar Rock's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$250,000.001,243.72$-16,410,000.00($2.80)-2.96
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

Cardiff Oncology has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cardiff Oncology has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Summary

Scholar Rock beats Cardiff Oncology on 8 of the 13 factors compared between the two stocks.


Cardiff Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65-10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.94-0.7%$1.16 billion$32.16 million-10.16Analyst Upgrade
Decrease in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$38.70-0.1%$1.14 billionN/A-16.12Analyst Downgrade
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.28-5.0%$1.11 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.78-6.4%$1.09 billionN/A-3.91Increase in Short Interest
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77-0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Curis logo
CRIS
Curis
1.3$11.49-6.3%$1.05 billion$10 million-14.01Increase in Short Interest
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$23.75-0.2%$905.75 millionN/A-9.81Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.61-3.2%$824.27 millionN/A0.00Lockup Expiration
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.04-3.5%$663.63 million$14.75 million-2.59Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08-1.6%$623.24 million$13.29 million-9.99
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.59-0.8%$615.82 millionN/A0.00Analyst Downgrade
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.61-7.1%$586.59 millionN/A0.00Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.57-3.9%$586.36 million$17.80 million-23.16Analyst Report
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.04-2.6%$538.67 millionN/A-2.45Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.55-4.1%$531.02 millionN/A-1.25
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.45-4.4%$529.86 millionN/A-5.89
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.77-1.9%$501.14 million$22.24 million-4.36Increase in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.12-7.0%$454.86 millionN/A-8.00Increase in Short Interest
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.42-2.3%$445.32 millionN/A0.00Analyst Report
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$10.35-11.1%$430.79 millionN/A-3.14Analyst Upgrade
News Coverage
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.64-2.4%$422.95 million$4.36 million-3.02
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.09-6.8%$412.63 million$147.87 million-3.02
Opthea logo
OPT
Opthea
1.5$9.10-0.4%$395.46 millionN/A0.00Lockup Expiration
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.70-0.1%$353.95 millionN/A0.00
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.44-3.2%$353.17 millionN/A0.00Analyst Report
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.40-0.0%$347.56 million$96.12 million-12.94
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.82-4.4%$315.96 million$8.15 million-1.46Increase in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.4$6.79-5.4%$283.33 million$15.36 million-10.29
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$12.88-3.3%$283.28 millionN/A0.00Analyst Report
Increase in Short Interest
Lockup Expiration
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.30-1.2%$281.38 millionN/A-3.42News Coverage
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.29-4.7%$276.91 million$2.91 million-1.84
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.70-0.5%$257.47 millionN/A-7.81
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.79-1.1%$250.24 million$4.13 million-3.98
INmune Bio logo
INMB
INmune Bio
1.5$13.62-20.9%$203.39 millionN/A-14.04
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.